Arbutus Biopharma Corporation (ABUS)

NASDAQ: ABUS · IEX Real-Time Price · USD
2.865
-0.025 (-0.87%)
May 14, 2024, 3:00 PM EDT - Market open
-0.87%
Market Cap 538.79M
Revenue (ttm) 12.99M
Net Income (ttm) -74.39M
Shares Out 188.72M
EPS (ttm) -0.44
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 300,981
Open 2.860
Previous Close 2.890
Day's Range 2.810 - 2.900
52-Week Range 1.690 - 3.290
Beta 2.05
Analysts Strong Buy
Price Target 4.33 (+51.66%)
Earnings Date May 2, 2024

About ABUS

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, ... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Michael J. McElhaugh
Employees 73
Stock Exchange NASDAQ
Ticker Symbol ABUS
Full Company Profile

Financial Performance

In 2023, ABUS's revenue was $18.14 million, a decrease of -53.51% compared to the previous year's $39.02 million. Losses were -$72.85 million, 4.89% more than in 2022.

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for ABUS stock is "Strong Buy." The 12-month stock price forecast is $4.33, which is an increase of 51.66% from the latest price.

Price Target
$4.33
(51.66% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Arbutus to Participate in Two Upcoming Investor Conferences

WARMINSTER, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a func...

7 days ago - GlobeNewsWire

Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update

End-of-treatment data from two Phase 2a combination clinical trials with imdusiran to be presented at the EASL Congress in June 2024

12 days ago - GlobeNewsWire

Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024

WARMINSTER, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virolog...

12 days ago - GlobeNewsWire

Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update

WARMINSTER, Pa., April 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a fu...

26 days ago - GlobeNewsWire

Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna

WARMINSTER, Pa., April 04, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a fu...

5 weeks ago - GlobeNewsWire

Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update

On-track to report key clinical data in 2024 from two on-going Phase 2a clinical trials with imdusiran and the Phase 1a/1b clinical trial with AB-101

2 months ago - GlobeNewsWire

Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update

WARMINSTER, Pa., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a fun...

3 months ago - GlobeNewsWire

Arbutus Announces 2024 Corporate Objectives and Provides Financial Update

Additional data from two on-going Phase 2a clinical trials evaluating imdusiran, our RNAi therapeutic, as a cornerstone therapy in combination with other compounds expected in 2024

4 months ago - GlobeNewsWire

Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®

The combination of imdusiran and VTP-300 provides a meaningful reduction of HBsAg levels that are maintained well below baseline

6 months ago - GlobeNewsWire

Arbutus to Present at Jefferies London Healthcare Conference

WARMINSTER, Pa., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virolo...

6 months ago - GlobeNewsWire

Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Multiple data presentations upcoming at AASLD – The Liver Meeting®, including preliminary data from Phase 2a clinical trial combining imdusiran, our RNAi therapeutic, with VTP-300, an HBV antigen-spec...

6 months ago - GlobeNewsWire

Arbutus Announces CEO, William Collier, to Retire December 31, 2023

Michael J. McElhaugh, Arbutus Co-founder and COO, to Serve as Interim CEO WARMINSTER, Pa., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), ...

6 months ago - GlobeNewsWire

Arbutus to Report Third Quarter 2023 Financial Results and Provide Corporate Update

WARMINSTER, Pa., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virolo...

7 months ago - GlobeNewsWire

Arbutus to Present at H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Virtual Conference

WARMINSTER, Pa., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virolo...

7 months ago - GlobeNewsWire

Arbutus Announces Multiple Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2023

Imdusiran data will be highlighted in late breaking presentation WARMINSTER, Pa., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical com...

7 months ago - GlobeNewsWire

Arbutus Announces Pipeline Updates and Dosing of the First Subject in the Phase 1a/1b Clinical Trial with AB-101; Cash Runway Extended

Progressing development of hepatitis B virus (HBV) compounds imdusiran (AB-729) and AB-101, an oral PD-L1 inhibitor

8 months ago - GlobeNewsWire

Arbutus Reports Second Quarter 2023 Financial Results and Corporate Update

Regulatory approval received in New Zealand to advance AB-101, our oral PD-L1 inhibitor, into a Phase 1 clinical trial with dosing to begin this quarter

10 months ago - GlobeNewsWire

Arbutus to Report Second Quarter 2023 Financial Results and Provide Corporate Update

WARMINSTER, Pa., July 20, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel...

10 months ago - GlobeNewsWire

Arbutus Appoints Melissa V. Rewolinski, PhD to its Board of Directors

WARMINSTER, Pa., July 12, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virolo...

10 months ago - GlobeNewsWire

Arbutus Appoints Two New Executives

Karen Sims, MD, PhD Promoted to Chief Medical Officer Christopher Naftzger Appointed as General Counsel and Chief Compliance Officer WARMINSTER, Pa., July 10, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharm...

11 months ago - GlobeNewsWire

Arbutus Doses First Patient in Additional Treatment Arm of Phase 2a Triple Combination Clinical Trial that Includes a PD-1 Monoclonal Antibody

Evaluating safety and efficacy of combining AB-729, VTP-300, nucleos(t)ide analogues and nivolumab (Opdivo®) WARMINSTER, Pa., June 21, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: A...

11 months ago - GlobeNewsWire

Arbutus Presents Preliminary AB-729 and Pegylated Interferon Alfa-2a Combination Data at the EASL Congress 2023

Treatment was generally well tolerated with continued HBsAg declines in some patients WARMINSTER, Pa., June 21, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the ...

11 months ago - GlobeNewsWire

Arbutus to Present AB-729 and AB-836 Data at EASL Congress 2023

WARMINSTER, Pa., June 07, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel...

1 year ago - GlobeNewsWire

Arbutus to Present at Jefferies Healthcare Conference

WARMINSTER, Pa., May 31, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virolog...

1 year ago - GlobeNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arbutus Biopharma Corporation - ABUS

NEW YORK , May 10, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Arbutus Biopharma Corporation ("Arbutus" or the "Company") (NASDAQ: ABUS). Such investors are ad...

1 year ago - PRNewsWire